SAB Biotherapeutics (SABS)
Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.
$3.38
vs last close−0.12 (−3.43%)
Something off on this page? Send us feedback.
Next report
Nov 13, 26
estimated · in 51 days
EPS estimate
−$0.27
Revenue estimate
$125.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.23−$0.56−$1.09−$0.21−$0.46−$0.35−$0.28Pending
Estimate−$1.16−$1.00−$0.82−$0.59−$0.16−$0.20−$0.28−$0.27
Surprise−6.0%+44.0%−32.9%+64.4%−187.5%−75.0%+1.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$100.0K——————Pending
Estimate$120.0K$125.0K$83.3K$100.0K$100.0K$125.0K$125.0K$125.0K
Surprise−16.7%———————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.19 | — | — |
| Sep 2027 | −$0.20 | — | — |
| Jun 2027 | −$0.21 | — | — |
| Mar 2027 | −$0.22 | — | — |
| Dec 2026 | −$0.27 | — | — |
| Nov 2026 | −$0.27 | — | — |
| Aug 2026 | −$0.28 | −$0.28 | +1.1% |
| May 2026 | −$0.20 | −$0.35 | −75.0% |
| Mar 2026 | −$0.16 | −$0.46 | −187.5% |
| Nov 2025 | −$0.59 | −$0.21 | +64.4% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Apr 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Apr 2021 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.19 | — | — | $0 | — | — | — |
| Sep 2027 | −$0.20 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.21 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.22 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.27 | — | — | $125.0K | — | — | — |
| Nov 13, 2026 | −$0.27 | — | — | $125.0K | — | — | — |
| Aug 6, 2026 | −$0.28 | −$0.28 | +1.1% | $125.0K | — | — | +2.1% |
| May 12, 2026 | −$0.20 | −$0.35 | −75.0% | $125.0K | — | — | −2.7% |
| Mar 9, 2026 | −$0.16 | −$0.46 | −187.5% | $100.0K | — | — | +6.8% |
| Nov 14, 2025 | −$0.59 | −$0.21 | +64.4% | $100.0K | — | — | +4.5% |
| Aug 7, 2025 | |||||||
| May 9, 2025 | |||||||
| Mar 28, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 20, 2024 | |||||||
| Apr 1, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 21, 2023 | |||||||
| May 16, 2023 | |||||||
| Apr 14, 2023 | |||||||
| Nov 15, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 29, 2022 | |||||||
| Nov 22, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 21, 2021 | |||||||
| Apr 2, 2021 |